COL19A1 and amyotrophic lateral sclerosis: In addition, time-dependent Cox regression analysis, using leave-one-out cross validation, suggested that the lifespan of sporadic ALS patients showing COL19A1 levels above average (0.819) and a faster progression of the disease (ALSFRS-r slope at sampling scores ≥ 1 points/month) was reduced 17.9% (HR: 1.179, CI: 1.046-1.327, P =0.007), similarly to the result obtained in the blood cohort.